Singapore
Sterile development and manufacturing
Singapore Sterile Fill Finish Facility
Thermo Fisher Scientific’s state-of-the-art sterile drug development and manufacturing facility in Singapore supports rapid fill finish vaccines and other therapeutics for an expanding biopharma market.
With support from the Singapore Economic Development Board, (EDB) this facility is an essential part of Thermo Fisher Scientific’s global network – now comprising of six facilities supporting aseptic manufacturing and sterile fill finish.
Our commitment to meeting scientists’ needs globally is further strengthened by this facility, which is designed to enhance our network for biomedical research, development, and commercialization.
Site Offerings
- The 24,000-sqaure-meter facility includes a high-speed, fully automated, aseptic fill-finish line for small and large molecules.
- Contains a single-use formulation system and custom scalability from small-scale process development to large clinical batches.
- Includes cleanroom capacity, labs, warehousing, and offices to support production.
- Carefully constructed with flexibility and scalability in mind – the potential for an additional 14,000 square meters of space to provide capacity for our customers’ growing needs.
- Additional space for filling lines and added capabilities for prefilled syringe & cartridges, filling line of smaller scale for process development and clinical trials, commercial sterile lyophilized lines and packaging.
To find out more about our unique site offerings, download our fact sheet below.
Capabilities
Existing Capabilities
- Jacketed tanks and disposable bag technology (Up to 1000L)
- Single use technologies and flexible facility design
- In house QC capabilities
- Sterile Liquids (SVP)
Biopharmaceuticals
- Commercial scale filling
- Process development / small scale filling
- Packaging
Expansion capabilities (not currently available)
- Sterile lyophilized products
- Prefilled syringes
- Prefilled catridges
Drug product dosage form
| Size / details | Early Development (into part of phase ll) | Late development | Commercial supply | |||||
|---|---|---|---|---|---|---|---|---|
| Liquid vials | ||||||||
| Lyophilized vials (Expansion) | ||||||||
| Prefilled syringes (Expansion) | ||||||||
| Prefilled cartridges (Expansion) | ||||||||
⬤ Available now
✱ Future capabilities
To learn more about this site or to request a site tour, please contact us below.
Helpful Resources
Inforgraphic
10 Reasons Formulation Complexity is on the Rise in Steriles
Within early development, there are a variety of different challenges that hinder a molecule’s ability to progress to the next phase such as complex formulation. The complexity of sterile drug development has been on the rise, which is driven by a variety of different factors.
View Infographic
Whitepaper
Switching delivery formats: A lifecycle management strategy for sterile injectables
Switching delivery formats can be an effective strategy to enhance they lifecycle of your drug. This whitepaper provides insight into the benefits and challenges of transferring a therapeutic compound from one aseptic injectable format to another.
View Whitepaper
Site Location
Brisbane, Australia
The Thermo Fisher Scientific site in Brisbane, Australia is a state of the art facility, specializing in clinical and commercial manufacturing, and single use biologics technology. The Brisbane facility won the ISPE “2014 Facility of the Year” for Process Innovation, and is part of our global network of Biologics sites, which also includes St. Louis Missouri and Groningen, Netherlands.
View Site Location
Site Location
Singapore (Clinical trial services)
Singapore is a hub to the Asia Pacific region due to its strategic location at the crossroads of international trade and shipping routes and its free trade policy.
Our highly experienced local Singapore team is supported by our network of Asia Pacific facilities, including Beijing & Suzhou in China, Japan, India and Korea, providing access to a global network with a local presence.
View Site Location